ASH 2024: Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care - Episode 10

An Overview to Myelofibrosis and Disease Risk

, , , ,

Panelists discuss myelofibrosis (MF) and its diagnostic workup, including how patients with primary MF present, the criteria required for diagnosis, and any additional biomarkers or criteria examined in practice.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Initial Treatment Strategies for Polycythemia Vera
    EP. 2: Cytoreductive Therapy in PV Treatment Paradigm
    EP. 3: JAK Inhibition in Polycythemia Vera: Treatment Updates
    EP. 4: Interferon Therapy in PV
    EP. 5: Safety Considerations for PV Therapy
    EP. 6: Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence
    EP. 7: Interferon Real- World Treatment Patterns in PV
    EP. 8: Considerations for Polycythemia Vera Management: Patient Monitoring, Outcomes, and Risks
    EP. 9: Future Considerations for Polycythemia Vera Management: Takeaways from ASH 2024
    Now Viewing
    EP. 10: An Overview to Myelofibrosis and Disease Risk
    EP. 11: Treatment Goals for Myelofibrosis
    EP. 12: Personalizing Therapy in Myelofibrosis: Insights from Key Clinical Trials
    EP. 13: Advancing Myelofibrosis Treatment: Personalized Strategies with Fedratinib and Ruxolitinib
    EP. 14: Real-World Data in Myelofibrosis: Bridging the Gap Between Clinical Trials and Practice
    EP. 15: Navigating Therapy Challenges in Myelofibrosis: Anemia Management and Disease-Specific Approaches
    EP. 16: Myelofibrosis at ASH 2024: Key Updates and Emerging Therapies
    EP. 17: MPN Milestones of 2024 and What’s Next for 2025

    Video content above is prompted by the following:

    • What outstanding updates in PV from ASH 2024 are noteworthy?
    • What do you see for the future of PV treatment?
    • What are the greatest unmet needs?
    • How are ongoing investigational therapies helping to address these unmet needs?
    • What clinical pearls can you share for community oncologists?
    x